Veeva Systems (VEEV)
(Delayed Data from NYSE)
$204.67 USD
+0.14 (0.07%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $204.53 -0.14 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$204.67 USD
+0.14 (0.07%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $204.53 -0.14 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Zacks News
Here's Why You Should Invest in Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to gain from its Mako robotics platform, which has been the key driver of the company's core Orthopaedic segment.
Is Veeva Systems (VEEV) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Veeva Systems (VEEV).
Walgreens (WBA) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Walgreens' (WBA) retail Pharmacy USA division witnessed comparable prescription growth and benefited from a strong retail prescription market.
Walgreens-Alphabet Join Forces to Control Healthcare Costs
by Zacks Equity Research
Walgreens (WBA) and Alphabet's arm Verily to start a medication adherence pilot project that will deploy equipment and other methods to improve adherence.
Myriad Genetics' New FDA Nod for BRACAnalysis CDx Widens Base
by Zacks Equity Research
Myriad Genetics (MYGN) progresses well with initiatives to boost the uptake of the BRACAnalysis CDx test. The recent approval to increase the customer base is an added positive.
Veeva Systems (VEEV) Stock Moves -0.88%: What You Should Know
by Zacks Equity Research
In the latest trading session, Veeva Systems (VEEV) closed at $87.08, marking a -0.88% move from the previous day.
Here's Why You Should Invest in STERIS (STE) Stock Right Now
by Zacks Equity Research
With the acquisition of U.K.-based outsourced sterilization services provider Synergy Health, STERIS (STE) has become the global leader in infection prevention and sterilization.
Abercrombie, Halliburton, Veeva, Attunity and Nice highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Abercrombie, Halliburton, Veeva, Attunity and Nice highlighted as Zacks Bull and Bear of the Day
Medtronic's Mazor Buyout Creates a New Spine Surgery Major
by Zacks Equity Research
With the acquisition of Mazor Robotics, Medtronic (MDT) expects to offer a fully-integrated procedural solution for surgical planning, execution and confirmation.
3 Cloud Stocks to Buy Right Now
by Ryan McQueeney
In a matter of just a few years, "the Cloud" has evolved from a budding new tech feature to one of the main factors driving growth in the technology sector. Check out these three cloud stocks to buy right now!
Veeva, Party City, Mellanox, Cree and Intel highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Veeva, Party City, Mellanox, Cree and Intel highlighted as Zacks Bull and Bear of the Day
GNC Holdings Global Business Strong, Same Store Sales Weak
by Zacks Equity Research
GNC Holdings' (GNC) domestic franchise revenues worsen due to soft retail same store sales and fewer franchise stores.
Here's Why You Should Buy Haemonetics (HAE) Stock Right Now
by Zacks Equity Research
Haemonetics (HAE) continues to witness strong growth in Plasma franchise.
Bull of the Day: Veeva Systems (VEEV)
by Madeleine Johnson
Estimates are swinging higher for this booming SaaS stock.
4 Medical Device Stocks That More Than Doubled in 2018
by Sweta Jaiswal
Here are four medical device stocks which have performed really well in 2018 and should be on investors' radar next year as well.
Hologic's (HOLX) New Offering to Revitalize Cynosure Division
by Zacks Equity Research
The latest launch along with certain new developments is expected to boost top-line contribution from Hologic's (HOLX) Cynosure division in the near term.
Bruker Profits from NANO & CALID, New Buyout Holds Promise
by Zacks Equity Research
Bruker (BRKR) looks to gain from high demand for ADVANCE X-ray and nano-analysis products. The CALID Group also raises hope with high-single digit robust year-to-date revenues.
Veeva Systems (VEEV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Veeva Systems (VEEV) closed the most recent trading day at $92.13, moving +0.1% from the previous trading session.
Thermo Fisher (TMO) Rides on New Buyouts and APAC Strength
by Zacks Equity Research
We are upbeat about Thermo Fisher's (TMO) recent buyout of Advanced Bioprocessing business, which will add complementary cell culture products to the company's bioproduction suit.
Edwards Lifesciences Advances in AI With Bay Labs Tie-Up
by Zacks Equity Research
Through the tie-up, Edwards Lifesciences (EW) aims at improving detection of heart diseases and enhancing quality by using Bay Labs' ability to apply AI to cardiovascular imaging.
CVS Health Aetna Synergy Impressive, PBM Selling Season Solid
by Zacks Equity Research
CVS Health (CVS) estimates a $750-million earning from near-term synergies with low- to mid-single digit addition in the second year after the closure of Aetna transaction.
STERIS Rides on Favorable Industry Trends, Rivalry a Concern
by Zacks Equity Research
STERIS (STE) is currently displaying strong top-line growth on encouraging market trends along with a new product and service portfolio.
NuVasive's Monolith Corpectomy System Ok'd for Expanded Use
by Zacks Equity Research
NuVasive's (NUVA) latest FDA 510 (k) clearance receipt is expected to augment customer base and market reach.
Hologic Unveils Omni Hysteroscope, Boosts GYN Surgical Arm
by Zacks Equity Research
Hologic (HOLX) highlights that a direct visualization of the uterine cavity in women with abnormal uterine bleeding will set a benchmark for the medical test.
Hill-Rom Adds New Capabilities to Centrella Smart+ Beds
by Zacks Equity Research
Hill-Rom (HRC) stays focused on expansion through product development. The latest move is expected to boost the top-line results of the company.